Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)
Sponsor: Adverum Biotechnologies, Inc.
Listed as NCT06856577, this PHASE3 trial focuses on Neovascular Age-Related Macular Degeneration (nAMD) and Wet AMD and remains actively recruiting participants. Sponsored by Adverum Biotechnologies, Inc., it has been updated 9 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
First recorded
Feb 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adverum Biotechnologies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .